	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Errors
1	BRS	L1	116266	promoter	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 12:35			0
2	BRS	L2	5516	constitutive adj promoter	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 12:35			0
3	BRS	L5	625	molecular adj switch	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 15:56			0
4	BRS	L7	0	5 same 3	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 12:36			0
5	BRS	L6	2	5 same 2	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 12:36			0
6	BRS	L8	91	(edwards adj cynthia.in.) or (fry adj kirk.in.) or (bruice adj thomas.in.) or (starr adj douglas.in.) or (laurance adj megan.in.) or (kwok adj	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 12:55			0
7	BRS	L9	0	5 and 8	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 12:58			0
8	BRS	L10	256	gene adj switch	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 12:58			0
9	BRS	L11	0	10 and 8	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 12:58			0
10	BRS	L12	1873	regulatable adj promoter	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 15:43			0
11	BRS	L13	2	5 same 12	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 15:42			0
12	BRS	L14	2	5527690.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 15:43			0
13	BRS	L15	0	12 and 14	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 15:44			0
14	BRS	L16	13445	inducible adj promoter	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 15:43			0

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Errors
15	BRS	L17	1028	12 and 16	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 15:44			0
16	BRS	L18	0	14 and 16	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 15:44			0
17	BRS	L19	856	5 or 10	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 15:57			0
18	BRS	L20	17692	(transcription adj factor) or (transcriptional adj regulatory adj protein) or (transcriptional adj regulatory adj factor) or (DNA adj binding adj protein)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 15:58			0
19	BRS	L21	3064	(inducer or compound) same (DNA adj binding)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:00			0
20	BRS	L22	1	19 same 20 same 21	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:41			0
21	BRS	L23	14558	dna adj binding	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:04			0
22	BRS	L24	661	20 same 21 same 23	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:09			0
23	BRS	L25	14290	12 or 16	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:05			0
24	BRS	L26	0	24 same 25 same transgene	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:06			0
25	BRS	L27	3688	adenovirus adj vector	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:07			0
26	BRS	L28	1381	adeno-associated adj virus adj vector	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:07			0
27	BRS	L30	0	29 same trangene	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:10			0
28	BRS	L31	15255	reporter adj gene	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:11			0

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Errors
29	BRS	L32	0	29 same 31	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:11			0
30	BRS	L29	18	20 same 19 same 23	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:24			0
31	BRS	L33	0	29 same (12 or 16)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:24			0
32	BRS	L34	286	DNA adj binding adj sequence	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:25			0
33	BRS	L35	11443	ul9 or NF-kappaB or gal4 or ZFHD1 orlacR or tetr lexa or (ecdysone adj receptor adj binding)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:27			0
34	BRS	L36	13319	vp16 or nf-kappaB or gal4 or tfe3 or itf1 or oct-1 or sp1 or oct-2 or nfy-a or itf or cmyc or ctf	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:31			0
35	BRS	L37	332178	kruppel or krab or kox-1 or tetr or even-skipped or lacr or engrailed or hairy or hes or groucho or tle or ring1 or ssb16 or ssb24 or tup1 or nab1 or areb or e4bp4 or hoxa7 or ebna3 or mad or v-erba	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:33			0
36	BRS	L38	2381	(36 or 37) same 20	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:35			0
37	BRS	L39	0	35 same 38 same 19	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:36			0
38	BRS	L40	70	(repressor or activator) same 19	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:37			0
39	BRS	L41	29	(repressor or activator) same 19 same 20	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:38			0
40	BRS	L42	0	41 same 21	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:38			0

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Errors
41	BRS	L43	2	41 same (dna adj binding)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:40			0
42	BRS	L44	0	8 and 19	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:40			0
43	BRS	L45	101	dna adj binding adj compound	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:41			0
44	BRS	L46	1	45 same 19	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/14 16:41			0

```
FILE 'MEDLINE' ENTERED AT 16:49:32    14 SEP 2003

FILE 'CAPLUS' ENTERED AT 16:49:32 ON 14 SEP 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 16:49:32 ON 14 SEP 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 16:49:32 ON 14 SEP 2003
COPYRIGHT (C) 2003 Elsevier Science B.V.  All rights reserved.

FILE 'SCISEARCH' ENTERED AT 16:49:32 ON 14 SEP 2003
COPYRIGHT 2003 THOMSON ISI

FILE 'AGRICOLA' ENTERED AT 16:49:32 ON 14 SEP 2003

=> s molecular switch
L1        4398 MOLECULAR SWITCH

=> s gene switch
L2         903 GENE SWITCH

=> s l1 or l2
L3        5291 L1 OR L2

=> s (transcription factor) or (transcriptional regulatory protein) or (transcriptional regulatory
   4 FILES SEARCHED...
L4      417831 (TRANSCRIPTION FACTOR) OR (TRANSCRIPTIONAL REGULATORY PROTEIN)
               OR (TRANSCRIPTIONAL REGULATORY FACTOR) OR (DNA BINDING PROTEIN)

=> s (inducer or compound)(p) (dna binding)
L5        7538 (INDUCER OR COMPOUND)(P) (DNA BINDING)

=> s l3 (p) l4 (p) l5
L6           6 L3 (P) L4 (P) L5

=> duplicate remove l6
DUPLICATE PREFERENCE IS 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH'
KEEP DUPLICATES FROM MORE THAN ONE FILE?  Y/(N):n
PROCESSING COMPLETED FOR L6
L7            2 DUPLICATE REMOVE L6 (4 DUPLICATES REMOVED)

=> d l7 1-2 ibib abs

L7   ANSWER 1 OF 2     MEDLINE on STN                    DUPLICATE 1
ACCESSION NUMBER:   2002635673     MEDLINE
DOCUMENT NUMBER:    22282001   PubMed ID: 12395191
TITLE:              A Renilla luciferase-Aequorea GFP (ruc-gfp) fusion gene
                    construct permits real-time detection of promoter
                    activation by exogenously administered mifepristone in
                    vivo.
AUTHOR:             Yu Y A; Szalay A A
CORPORATE SOURCE:   Division of Human Anatomy, Loma Linda University School of
                    Medicine, Loma Linda, CA 92350, USA.
SOURCE:             Mol Genet Genomics, (2002 Oct) 268 (2) 169-78.
                    Journal code: 101093320. ISSN: 1617-4615.
PUB. COUNTRY:       Germany: Germany, Federal Republic of
DOCUMENT TYPE:      Journal; Article; (JOURNAL ARTICLE)
LANGUAGE:           English
FILE SEGMENT:       Priority Journals
ENTRY MONTH:        200212
ENTRY DATE:         Entered STN: 20021024
                    Last Updated on STN: 20030105
                    Entered Medline: 20021213
AB   In this study, we used a steroid-induced promoter activation system as a
       ***molecular***     ***switch***   to study the exogenous activation of
     transgene expression.  This promoter activation system consists of three
     components: (1) a steroidal   ***inducer***   drug, mifepristone (RU486),
     which binds to (2) a chimeric   ***transcription***     ***factor***
     complex, consisting of the mutant human progesterone receptor fused to the
     yeast GAL4   ***DNA***  -  ***binding***   domain and the activation
     domain of the herpes simplex virus protein VP16, and (3) a synthetic
     promoter, consisting of a series of GAL4 recognition sequences upstream of
     the adenovirus major late E1B TATA box, linked to a gene construct
```

(ruc-gfp) encoding a Renilla luciferase- Aequorea green fluorescent protein (GFP) fusion protein. [redacted]ranscription of the promoter-ma[redacted]er gene cassette is activated by the drug (mifepristone)-bound chimeric ***transcription*** ***factor*** complex. Monitoring of induced gene expression was carried out using a low-light video camera and a UV microscope to detect luciferase and GFP, respectively. Using this activation system, we observed a 10- to 25-fold activation, depending on the ***inducer*** dose, of both luciferase and GFP expression in transiently transfected cells in comparison to cells that were not exposed to mifepristone. We further demonstrated activation of gene expression from the promoter activation system in live animals. The plasmids PAP CMV-GL914VPc'SV, carrying the chimeric ***transcription*** ***factor*** cassette, and plasmid p17x4-TATA-ruc-gfp, carrying the ruc-gfp reporter gene construct, were co-injected into limb muscles of nude mice. Following DNA injection, mifepristone (50 micro g/kg) was delivered by intraperitoneal injection. Thirty-six hours after DNA and mifepristone injection, significant Renilla luciferase activity was detectable in the limb muscles. The promoter activation system was also demonstrated in limb muscles and livers of nude mice that had received transplants of ex vivo-modified cells, which were transiently transformed with both the chimeric activator plasmid and the ruc-gfp reporter plasmid prior to implantation. Significant Renilla activity and GFP fluorescence were detected externally in limb muscles and in the livers of anesthetized animals that had received an intraperitoneal injection of ***inducer*** . This external monitoring method for observing inducible gene expression in live animals will facilitate experimental studies of fundamental questions of biological and therapeutic relevance. It will be especially valuable for the analysis of gene function at specific stages of animal development. The method should also be of general use in gene therapy, since it permits simultaneous monitoring of the expression levels of light-emitting proteins and therapeutic proteins originating from the activation of identical promoters.

L7 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2000:628284 CAPLUS
DOCUMENT NUMBER: 133:233573
TITLE: Inducible regulatory systems for control of gene expression
INVENTOR(S): Lim, Moon Young; Edwards, Cynthia A.; Fry, Kirk E.; Bruice, Thomas W.; Starr, Douglas B.; Laurance, Megan E.; Kwok, Yan
PATENT ASSIGNEE(S): Genelabs Technologies, Inc., USA
SOURCE: PCT Int. Appl., 92 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000052179	A2	20000908	WO 2000-US5728	20000303
WO 2000052179	A3	20001221		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1165808	A2	20020102	EP 2000-913742	20000303
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRIORITY APPLN. INFO.: US 1999-122513P P 19990303
US 1999-154605P P 19990917
WO 2000-US5728 W 20000303

AB Inducible gene expression systems regulated by a ligand are described. The system includes a nucleic acid construct which has a DNA response sequence for a ***transcriptional*** ***regulatory*** ***protein*** operably linked to a promoter, a ***compd*** . binding sequence in the vicinity of the DNA response sequence, a transgene under the control of the promoter; and a ***DNA*** ***binding*** ***compd*** . In some cases, the ***mol*** . ***switch*** system further includes a nucleic acid sequence encoding a ***transcriptional*** ***regulatory*** ***protein*** operably

linked to a second promoter. The invention further provides a method for screening ***compds*** . for the ability to function in the ***mol*** . ***switch*** system and thereby regulate gene expression.

```
=> d his

     (FILE 'HOME' ENTERED AT 16:49:01 ON 14 SEP 2003)

     FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT
     16:49:32 ON 14 SEP 2003
L1          4398 S MOLECULAR SWITCH
L2           903 S GENE SWITCH
L3          5291 S L1 OR L2
L4        417831 S (TRANSCRIPTION FACTOR) OR (TRANSCRIPTIONAL REGULATORY PROTEIN
L5          7538 S (INDUCER OR COMPOUND)(P) (DNA BINDING)
L6             6 S L3 (P) L4 (P) L5
L7             2 DUPLICATE REMOVE L6 (4 DUPLICATES REMOVED)

=> s dna binding
L8        254485 DNA BINDING

=> s l3 (p) l4
L9            362 L3 (P) L4

=> s l9 (p) l8
L10           105 L9 (P) L8

=> s transgene or (reporter gene)
L11       163288 TRANSGENE OR (REPORTER GENE)

=> s l10 (p) l11
L12            17 L10 (P) L11

=> s promoter
L13       572487 PROMOTER

=> s l12 (p) l13
L14             7 L12 (P) L13

=> duplicate remove l14
DUPLICATE PREFERENCE IS 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH'
KEEP DUPLICATES FROM MORE THAN ONE FILE?  Y/(N):n
PROCESSING COMPLETED FOR L14
L15             3 DUPLICATE REMOVE L14 (4 DUPLICATES REMOVED)

=> s l15 not l7
L16             1 L15 NOT L7

=> d l16 1 ibib abs

L16  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER:         2001:545853  CAPLUS
DOCUMENT NUMBER:          135:148182
TITLE:                    Molecular switches II system comprising
                          ligand-regulated DNA binding molecule and targeted DNA
                          binding site and its use in screening for desired
                          binding elements and gene regulation
INVENTOR(S):              Choo, Yen; Ullman, Christopher Graeme; Moore, Michael
PATENT ASSIGNEE(S):       Gendaq Limited, UK
SOURCE:                   PCT Int. Appl., 193 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   6
PATENT INFORMATION:

     PATENT NO.         KIND  DATE          APPLICATION NO.  DATE
     ---------------    ----  --------      ---------------  --------
     WO 2001053479       A2   20010726      WO 2001-GB187    20010118
     WO 2001053479       A3   20020131
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
             HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
             LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
             SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
             YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
```

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

WO 2000073434 A1 20001207 WO 2000-GB2071 20000530

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,
CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD,
SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,
ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

WO 2001000815 A1 20010104 WO 2000-GB2080 20000530

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,
CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD,
SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,
ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

GB 2000-1578	A	20000124
GB 2000-1582	A	20000124
WO 2000-GB2071	W	20000530
WO 2000-GB2080	W	20000530
GB 2000-29901	A	20001207
GB 1999-12635	A	19990528

AB A ***gene*** ***switch*** system comprising (i) a target nucleic acid mol.; (ii) a nucleic acid binding mol. which binds to the target nucleic acid mol. in a manner modulatable by a ligand; and (iii) the ligand is described. The ***DNA*** - ***binding*** ligand can modulate the interaction of the other two elements of the system which may both be derived from random libraries. The system is particularly intended for use to identify nucleic acid binding mols., targeted nucleic acid binding sites and modulating ligands, and to regulate transcription from one or more ***promoters*** in gene regulation. The selection of derivs. of the middle zinc finger of the ***transcription*** ***factor*** zif268 with altered ***DNA*** ***binding*** from a phage display library in the presence of small mols. including Distamycin A, or actinomycin D, or echinomycin is presented. The ***DNA*** ***binding*** activity of these isolated phage clones are also modulated by ligands and their use in gene regulation are tested in vitro binding assay. The zinc finger ***DNA*** ***binding*** domain is also converted to the catalytic domain of FokI restriction enzyme for ligand modulation. The isolated zinc finger clones and HSV VP16 activation domain fusion protein is prepd. and the modulation of its transcriptional activity by ligands is demonstrated with a ***reporter*** ***gene*** in vivo. Methods of isolating cognate target nucleic acids and screening for ligands, which affect the binding of a ***DNA*** ***binding*** mol. to its cognate DNA target, are described by using 434 repressor of phage 434. The zinc finger protein/drug/DNA microarrays are also provided for the selection purpose.

=> d his

(FILE 'HOME' ENTERED AT 16:49:01 ON 14 SEP 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT 16:49:32 ON 14 SEP 2003

L1	4398	S MOLECULAR SWITCH
L2	903	S GENE SWITCH
L3	5291	S L1 OR L2
L4	417831	S (TRANSCRIPTION FACTOR) OR (TRANSCRIPTIONAL REGULATORY PROTEIN
L5	7538	S (INDUCER OR COMPOUND)(P) (DNA BINDING)
L6	6	S L3 (P) L4 (P) L5
L7	2	DUPLICATE REMOVE L6 (4 DUPLICATES REMOVED)
L8	254485	S DNA BINDING
L9	362	S L3 (P) L4
L10	105	S L9 (P) L8
L11	163288	S TRANSGENE OR (REPORTER GENE)
L12	17	S L10 (P) L11
L13	572487	S PROMOTER
L14	7	S L12 (P) L13
L15	3	DUPLICATE REMOVE L14 (4 DUPLICATES REMOVED)

```
L16           1 S L15 NOT L7

=> s (regulatable or inducible) (w) promoter
L17        7266 (REGULATABLE OR INDUCIBLE) (W) PROMOTER

=> s l12 (p) l17
L18           0 L12 (P) L17

=> s nf-kappaB
L19       23346 NF-KAPPAB

=> s ul9 or gal4 or zfhd1 or lacr or tetr or lexa or (ecdysone receptor binding)
L20       20191 UL9 OR GAL4 OR ZFHD1 OR LACR OR TETR OR LEXA OR (ECDYSONE RECEPT
                OR BINDING)

=> s l19 or l20
L21       43442 L19 OR L20

=> s vp16 or nf-kappab or gal4 or tfe3 or itf1 or oct-1 or sp1 or oct-2 or nfy-a or itf2 or cmyc o
L22       83638 VP16 OR NF-KAPPAB OR GAL4 OR TFE3 OR ITF1 OR OCT-1 OR SP1 OR
                OCT-2 OR NFY-A OR ITF2 OR CMYC OR CTF

=> s kruppel or krab or kox-1 or tetr or even-skipped or lacr or engrailed o hairy or hes or grouc
L23       33096 KRUPPEL OR KRAB OR KOX-1 OR TETR OR EVEN-SKIPPED OR LACR OR
                ENGRAILED O HAIRY OR HES OR GROUCHO OR TLE OR RING1 OR SSB16 OR
                SSB24 OR TUP1 OR NAB1 OR AREB OR E4BP4 OR HOXA7 OR EBNA3 OR MAD
                OR V-ERBA

=> s (l22 or l23) (p) l4
L24       35250 (L22 OR L23) (P) L4

=> s l21 (p) l8
L25        9870 L21 (P) L8

=> s l3 (p) l24 (p) l25
L26           8 L3 (P) L24 (P) L25

=> duplicate remove l26
DUPLICATE PREFERENCE IS 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH'
KEEP DUPLICATES FROM MORE THAN ONE FILE?  Y/(N):n
PROCESSING COMPLETED FOR L26
L27            4 DUPLICATE REMOVE L26 (4 DUPLICATES REMOVED)

=> s l27 not (l7 or l16)
L28           3 L27 NOT (L7 OR L16)

=> d l28 1-3 ibib abs

L28  ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER:         2002:927602  CAPLUS
DOCUMENT NUMBER:          138:20483
TITLE:                    An GHRH (somatoliberin) expression system inducible by
                          a ligand-specific Gene-Switch regulator protein and
                          therapeutic uses
INVENTOR(S):              Nordstrom, Jeffrey L.; Draghia-Akli, Ruxandra
PATENT ASSIGNEE(S):       Valentis, Inc., USA; Baylor College of Medicine
SOURCE:                   PCT Int. Appl., 90 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.        KIND  DATE          APPLICATION NO.  DATE
     ---------------   ----  --------      ---------------  --------
     WO 2002097099      A1   20021205      WO 2001-US17573  20010530
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
             HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
             LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,
             RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
             VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.:                    US 2001-294316P  P  20010529
AB   The present invention provides for a regulated gene expression system for
```

growth hormone releasing hormone ("GHRH") characterized by low basal expression and high specific inducibility. The inducible-expression system includes two expression cassettes. The first expression cassette includes a promoter driving the expression of a mol.-switch fusion protein which comprises a DNA binding domain, a transactivation domain and a ligand-binding domain. The fusion protein is characterized by an inability to auto-dimerize in the absence of an ligand-inducer. The second expression cassette includes the gene encoding GHRH controlled by an inducible promoter which is activated by the fusion protein dimerizing in the presence of the inducer and binding to the promoter. The present invention includes therapeutic methods for treating growth hormone-related deficiencies assocd. with the growth hormone pathway; growth hormone-related deficiencies assocd. with genetic disease; wasting symptoms assocd. with burn, trauma, cancer, AIDS, and bone loss, as in elderly, or post-fracture. By administering an exogenously supplied inducer the expression system can be activated and controlled.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:927555 CAPLUS
DOCUMENT NUMBER: 138:19945
TITLE: Estrogen receptor ligand binding domain variants and prepn. of novel ligands and use to construct mol. gene switches for pharmaceutical use
INVENTOR(S): Bracken, Kathryn Rene; De Los Angeles, Joseph E.; Huang, Ying; Kadan, Michael J.; Ksander, Gary M.; Zerby, Dennis B.
PATENT ASSIGNEE(S): Novartis AG, Switz.
SOURCE: PCT Int. Appl., 159 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002097050	A2	20021205	WO 2002-US16946	20020531
WO 2002097050	A3	20030313		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003143559	A1	20030731	US 2002-157899	20020531

PRIORITY APPLN. INFO.: US 2001-294839P P 20010531

AB Mutants of steroid receptor ligand binding domains and synthetic ligands which have specific binding affinities for these receptors are provided. The use of these LBD-ligand combinations for construction of selective "mol. gene switches" is disclosed. Methods of regulating gene function using these switches are provided as are pharmaceutical compns. contg. the novel ligands.

L28 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1999:477732 CAPLUS
DOCUMENT NUMBER: 131:223928
TITLE: Development of gene-switch transgenic mice that inducibly express transforming growth factor .beta.1 in the epidermis
AUTHOR(S): Wang, Xiao-Jing; Liefer, Kristin M.; Tsai, Sophia; O'Malley, Bert W.; Roop, Dennis R.
CORPORATE SOURCE: Department of Cell Biology and Dermatology, Baylor College of Medicine, Houston, TX, 77030, USA
SOURCE: Proceedings of the National Academy of Sciences of the United States of America (1999), 96(15), 8483-8488
CODEN: PNASA6; ISSN: 0027-8424
PUBLISHER: National Academy of Sciences
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Previous attempts to establish transgenic mouse models to study the functions of transforming growth factor .beta.1 (TGF.beta.1) in the skin

revealed controversial roles f[redacted] TGF.beta.1 in epidermal growth (inhibition vs. stimulation) a[redacted] resulted in neonatal lethality[redacted] one instance. To establish a viable transgenic model for studying functions of TGF.beta.1 in the skin, we have now developed transgenic mice, which allow focal induction of the TGF.beta.1 transgene in the epidermis at different expression levels and at different developmental stages. This system, termed "gene-switch," consists of two transgenic lines. The mouse loricrin vector targets the GLVPc transactivator (a fusion mol. of the truncated progesterone receptor and the GAL4 DNA binding domain), and a thymidine kinase promoter drives the TGF.beta.1 target gene with GAL4 binding sites upstream of the promoter. These two transgenic lines were mated to generate bigenic mice, and TGF.beta.1 transgene expression was controlled by topical application of an antiprogestin. On epidermal-specific induction of the TGF.beta.1 transgene, the BrdUrd labeling index in the transgenic epidermis decreased 6-fold compared with controls. Induction of the TGF.beta.1 transgene expression also caused epidermal resistance to phorbol 12-myristate 13-acetate-induced hyperplasia, with a redn. in both epidermal thickness and BrdUrd labeling compared with those in controls. In addn., TGF.beta.1 transgene expression induced an increase in angiogenesis in the dermis. Given that the TGF.beta.1 transgene can affect both the epidermis and dermis, this transgenic model will provide a useful tool for studying roles of TGF.beta.1 in wound-healing and skin carcinogenesis in the future.

REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 16:49:01 ON 14 SEP 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT 16:49:32 ON 14 SEP 2003

```
L1          4398 S MOLECULAR SWITCH
L2           903 S GENE SWITCH
L3          5291 S L1 OR L2
L4        417831 S (TRANSCRIPTION FACTOR) OR (TRANSCRIPTIONAL REGULATORY PROTEIN
L5          7538 S (INDUCER OR COMPOUND)(P) (DNA BINDING)
L6             6 S L3 (P) L4 (P) L5
L7             2 DUPLICATE REMOVE L6 (4 DUPLICATES REMOVED)
L8        254485 S DNA BINDING
L9           362 S L3 (P) L4
L10          105 S L9 (P) L8
L11       163288 S TRANSGENE OR (REPORTER GENE)
L12           17 S L10 (P) L11
L13       572487 S PROMOTER
L14            7 S L12 (P) L13
L15            3 DUPLICATE REMOVE L14 (4 DUPLICATES REMOVED)
L16            1 S L15 NOT L7
L17         7266 S (REGULATABLE OR INDUCIBLE) (W) PROMOTER
L18            0 S L12 (P) L17
L19        23346 S NF-KAPPAB
L20        20191 S UL9 OR GAL4 OR ZFHD1 OR LACR OR TETR OR LOR (ECDYSONE RECEPTO
L21        43442 S L19 OR L20
L22        83638 S VP16 OR NF-KAPPAB OR GAL4 OR TFE3 OR ITF1 OR OCT-1 OR SP1 OR
L23        33096 S KRUPPEL OR KRAB OR KOX-1 OR TETR OR EVEN-SKIPPED OR LACR OR E
L24        35250 S (L22 OR L23) (P) L4
L25         9870 S L21 (P) L8
L26            8 S L3 (P) L24 (P) L25
L27            4 DUPLICATE REMOVE L26 (4 DUPLICATES REMOVED)
L28            3 S L27 NOT (L7 OR L16)

=> s lim moon/au
L29            2 LIM MOON/AU

=> s edwards cynthia/au
L30            5 EDWARDS CYNTHIA/AU

=> s fry kirk/au
L31           24 FRY KIRK/AU

=> s bruice thomas/au
L32            9 BRUICE THOMAS/AU

=> s starr douglas/au
L33            2 STARR DOUGLAS/AU
```

```
=> s laurance magan/au
L34             0 LAURANCE MAGAN/AU

=> kwok yan/au
KWOK IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s kwok yan/au
L35            26 KWOK YAN/AU

=> s l29 or l30 or l31 or l32 or l33 or l35
L36            68 L29 OR L30 OR L31 OR L32 OR L33 OR L35

=> s l36 and l1
L37             1 L36 AND L1

=> s l37 not l7
L38             0 L37 NOT L7

=> d his

     (FILE 'HOME' ENTERED AT 16:49:01 ON 14 SEP 2003)

     FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT
     16:49:32 ON 14 SEP 2003
L1           4398 S MOLECULAR SWITCH
L2            903 S GENE SWITCH
L3           5291 S L1 OR L2
L4         417831 S (TRANSCRIPTION FACTOR) OR (TRANSCRIPTIONAL REGULATORY PROTEIN
L5           7538 S (INDUCER OR COMPOUND)(P) (DNA BINDING)
L6              6 S L3 (P) L4 (P) L5
L7              2 DUPLICATE REMOVE L6 (4 DUPLICATES REMOVED)
L8         254485 S DNA BINDING
L9            362 S L3 (P) L4
L10           105 S L9 (P) L8
L11        163288 S TRANSGENE OR (REPORTER GENE)
L12            17 S L10 (P) L11
L13        572487 S PROMOTER
L14             7 S L12 (P) L13
L15             3 DUPLICATE REMOVE L14 (4 DUPLICATES REMOVED)
L16             1 S L15 NOT L7
L17          7266 S (REGULATABLE OR INDUCIBLE) (W) PROMOTER
L18             0 S L12 (P) L17
L19         23346 S NF-KAPPAB
L20         20191 S UL9 OR GAL4 OR ZFHD1 OR LACR OR TETR OR LOR (ECDYSONE RECEPTO
L21         43442 S L19 OR L20
L22         83638 S VP16 OR NF-KAPPAB OR GAL4 OR TFE3 OR ITF1 OR OCT-1 OR SP1 OR
L23         33096 S KRUPPEL OR KRAB OR KOX-1 OR TETR OR EVEN-SKIPPED OR LACR OR E
L24         35250 S (L22 OR L23) (P) L4
L25          9870 S L21 (P) L8
L26             8 S L3 (P) L24 (P) L25
L27             4 DUPLICATE REMOVE L26 (4 DUPLICATES REMOVED)
L28             3 S L27 NOT (L7 OR L16)
L29             2 S LIM MOON/AU
L30             5 S EDWARDS CYNTHIA/AU
L31            24 S FRY KIRK/AU
L32             9 S BRUICE THOMAS/AU
L33             2 S STARR DOUGLAS/AU
L34             0 S LAURANCE MAGAN/AU
L35            26 S KWOK YAN/AU
L36            68 S L29 OR L30 OR L31 OR L32 OR L33 OR L35
L37             1 S L36 AND L1
L38             0 S L37 NOT L7

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   194.07     194.28

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -3.26      -3.26

STN INTERNATIONAL LOGOFF AT 17:11:25 ON 14 SEP 2003
```